相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Are three drugs for malaria better than two?
Philip J. Rosenthal
LANCET (2020)
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
Rob W. van der Pluijm et al.
LANCET (2020)
Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in Plasmodium falciparum-Parasitized Erythrocytes
Ioannis Tsamesidis et al.
ANTIOXIDANTS (2020)
Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia
Kristina Kesely et al.
PLOS ONE (2020)
Antimalarial drug resistance in Africa: the calm before the storm?
Melissa D. Conrad et al.
LANCET INFECTIOUS DISEASES (2019)
Clinical impact of the two ART resistance markers, K13 gene mutations and DPC3 in Vietnam
Maria Carmina Pau et al.
PLOS ONE (2019)
Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!
Christian Nsanzabana
TROPICAL MEDICINE AND INFECTIOUS DISEASE (2019)
Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling
Saber Dini et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination
Manel Ouji et al.
PARASITE (2018)
Emergence of Indigenous Artemisinin-Resistant Plasmodium falciparum in Africa
Feng Lu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Syk inhibitors interfere with erythrocyte membrane modification during P falciparum growth and suppress parasite egress
Antonella Pantaleo et al.
BLOOD (2017)
Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia
Kristina R. Kesely et al.
PLOS ONE (2016)
Global transformation of erythrocyte properties via engagement of an SH2-like sequence in band 3
Estela Puchulu-Campanella et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Delayed Parasite Clearance after Treatment with Dihydroartemisinin-Piperaquine in Plasmodium falciparum Malaria Patients in Central Vietnam
Kamala Thriemer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
M. Pretel-Irazabal et al.
ACTAS DERMO-SIFILIOGRAFICAS (2014)
New antimalarial indolone-N-oxides, generating radical species, destabilize the host cell membrane at early stages of Plasmodium falciparum growth: role of band 3 tyrosine phosphorylation
Antonella Pantaleo et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
The proteome of erythrocyte-derived microparticles from plasma: new clues for erythrocyte aging and vesiculation
Giel J. C. G. M. Bosman et al.
JOURNAL OF PROTEOMICS (2012)
Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3
Emanuela Ferru et al.
BLOOD (2011)
Irreversible AE1 Tyrosine Phosphorylation Leads to Membrane Vesiculation in G6PD Deficient Red Cells
Antonella Pantaleo et al.
PLOS ONE (2011)
Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum
Lev Solyakov et al.
NATURE COMMUNICATIONS (2011)
Analysis of changes in tyrosine and serine phosphorylation of red cell membrane proteins induced by P. falciparum growth
Antonella Pantaleo et al.
PROTEOMICS (2010)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase
S Atwell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
